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Objectives: The behavior of the aneurysm sac after endovascular grafting has been the subject of significant speculation.
The importance of sac behavior is manifested by the correlation between aneurysm size or size change and risk for rupture,
and potentially further extrapolated to define the need for secondary intervention. This study was undertaken to define
graft-specific differences and the effect of endoleak on sac remodeling.
Methods: Core laboratory data were obtained for three US Phase II clinical trials. Patients were included if they met
anatomic inclusion criteria and underwent placement of the latest version of a bifurcated endovascular prosthesis.
Unsupported Dacron (Ancure), supported Dacron (Zenith), and expanded polytetrafluoroethylene (Excluder) grafts
were evaluated. Digitized images were electronically assessed for aneurysm size (area, maximum, minimum diameter)
with National Institutes of Health Image software. Two blinded reviewers analyzed each radiographic study to ensure
accurate image selection and establish the presence or absence of endoleak. A third reviewer adjudicated discrepancies. 2
analysis and mixed nonlinear modeling were used to analyze the results.
Results: Of 1506 patients evaluated, 723 (227 Ancure, 343 Excluder, 153 Zenith) met inclusion criteria for the study.
Mean follow-up was 23.2 months (Ancure, 31.3 months; Excluder, 19.6 months; Zenith, 19.3 months). The incidence
of any endoleak was 39.1% (Ancure, 58.1%; Excluder, 34.7%; Zenith, 20.9%; P < .001). Type of prosthesis, presence or
absence of endoleak, and baseline size were determinants of rate of aneurysm shrinkage. Reduction in sac size was greatest
with the Zenith graft, followed by the Ancure and Excluder grafts. Presence of endoleak had a moderating effect on rate
of sac shrinkage with the Zenith and Ancure grafts; however, sac size increased in the presence of endoleak with the
Excluder graft. Finally, baseline size was positively correlated with rate of aneurysm shrinkage.
Conclusions: The behavior of the aneurysm sac depends on the type of prosthesis, presence or absence of endoleak, and
baseline size of the sac. Differential sac behavior must be considered when determining the need for secondary
interventions, timing follow-up studies, and assessing success or failure of endovascular repair. (J Vasc Surg 2004;39:
95-101.)
Management of abdominal aortic aneurysms with en-
dovascular prostheses is widely practiced throughout the
world. Multiple endografts have been developed, and im-
planted with a variety of techniques. Choice of implant type
is largely determined by the clinician, on the basis of patient
anatomy, physiology, and device familiarity. However, after
implantation, devices have differing effects on the aortic
wall, as a result of various patient-related and prosthesis-
related factors.1,2 Investigators have hypothesized several
mechanisms to explain these observations, including differ-
ences in graft materials, modularity, presence of endoleak,
and overall device configuration.3-10 Reporting standards
have been developed in an attempt to unify methods of
conveying size changes after endovascular aneurysm re-
pair.11 However, the mechanisms by which sac changes
occur, influencing factors, and predictable outcomes have
been poorly defined in previous reports. A more detailed
understanding of sac behavior is critical to enable clinicians
to develop an understanding of how aneurysms are ex-
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pected to behave after implantation of a given brand of
endoprosthesis.
The implications of sac changes relate to the perceived
need for secondary intervention, expected effect of en-
doleak, and morphologic changes associated with device
stability and integrity. Furthermore, follow-up algorithms
are intended to enable early detection of potential instabil-
ity of the device predicting risk for rupture. To date these
regimens have been uniform to all prostheses. As we de-
velop a better understanding of expected sac behavior it
may be prudent to maintain a relatively intensive follow-up
protocol during periods of rapid sac change, whereas in the
setting of a stable sac or completely regressed aneurysm
follow-up intensiveness may be stepped down. We ascer-
tained core laboratory data from three prospective clinical
trials, with the intent to describe expected effects of the
three devices on the aneurysm wall in the presence and
absence of endoleak.
MATERIAL AND METHODS
Imaging data for all patients enrolled in the Ancure
(Guidant, Menlo Park, Calif), Excluder (W. L. Gore, Flag-
staff, Ariz), and Zenith (Cook Inc, Bloomington, Ind)
prospective trials were collected and stored in three separate
databases. Patients were enrolled at multiple centers
throughout the United States. Institutional review boards
had approved all investigational protocols at each site. All
data were retrospectively evaluated for inclusion in this
study. Each corporate trial sponsor identified an author
who would be most familiar with their graft and any graft-
specific or trial-specific issues that might pertain to analysis
of the data (D. D, Guidant; T. S., Gore; R. K. G., Cook).
In an attempt to limit the comparison to patients with
similar preoperative anatomy and established devices, spe-
cific inclusion criteria were established. Data for each study
were reviewed, and patients were included in this analysis
only if they met the anatomic inclusion criteria for their
respective trial. Although there were slight variations re-
garding anatomic inclusion criteria (Table I), requirements
were remarkably similar for the three trials. Further consid-
eration for inclusion in this analysis was given only to those
patients with implantation of the latest iteration of a bifur-
cated endoprosthesis in the particular trial. Patients with
aortomonoiliac devices and early iterations of graft designs
were excluded. Thus patients were included in the analysis
if they met the respective study criteria according to core
laboratory interpretation of films, had received the most
recent bifurcated device, and had follow-up data beyond
the immediate pre-discharge computed tomography (CT)
scan.
The core laboratory review process was standardized
for each trial. All CT scans were digitally evaluated on a
modified version of National Institutes of Health (NIH)
image software (available at: http://rsb.info.nih.gov/nih-
image). Edge detection and tracing were completed on
selected images that represented the proximal neck, maxi-
mum aneurysm size, and iliac diameter. To ensure appro-
priate image selection, only analyzers specifically trained to
assess CT scans for endovascular grafts performed image
selection. In an effort to obtain the highest degree of
accuracy, three images proximal and distal to the selected
image were also evaluated. Computerized techniques pro-
vided area measurement for individual image sections. Area
was calculated with the NIH Image software using a poly-
gon fill algorithm. A pixel mask was created, with the outer
border of the aneurysm wall used to define the area. The
calibrated scale was digitally entered, and used to quantify
the area (number of pixels) within the aneurysm sac. Area
assignment is a measured value, not mathematically derived
from the best-fit ellipse equation. The geometric center of
the sac is then determined by averaging the x and y coor-
dinates. Maximum and minimum diameters were defined
as the longest and shortest paths that traverse the aneurysm,
outer wall to outer wall, through the geometric center of
the axial image with the largest calculated area.
In addition to the initial analyzer, at least one medical
reviewer (a physician who had completed at least 1 year of
vascular surgery fellowship with an endovascular rotation,
or a radiology resident who had completed a body imaging
rotation) reviewed all images, to confirm appropriate image
selection and proper tracing of the aneurysm, and to pro-
vide an independent assessment of the presence or absence
of endoleak. Any discrepancies between analysts and med-
ical reviewers, as well as all instances that were thought to
represent major radiographic events (evidence of migra-
tion, type I or type III endoleak, device integrity issues),
were brought to the attention of the principal investigator
supervising the core laboratory study.
Patients noted to have endoleaks at any time during the
analysis were identified, and their data were analyzed in a
Table I. Anatomic inclusion criteria for three trials
Ancure Excluder Zenith
Proximal neck diameter (mm) 18-26 18-25 18-28
Minimum proximal neck length (mm) 15 15 15
Maximal proximal neck angulation Not specified 60° 60°
Minimum aneurysm size (mm) Not specified 45 40
Iliac artery diameter (mm) 8-13.4 8-13 8-20
Minimum iliac fixation length (mm) 20 20 10
Proximal neck thrombus Noncircumferential Noncircumferential Noncircumferential
It is important to note diameter differences between studies, as they represent variability within this core laboratory analysis. Remainder of specifications are in
accordance with trial design and largely reflect instructions for use that accompany each device.
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binary manner. Although the definition of endoleak was
identical for each of the trials, patients were enrolled at
different times with respect to evolution of core laboratory
imaging protocols and site requirements. The latter two
studies (Excluder, Zenith) had more complete, and in
general higher, resolution imaging data compared with the
first trial (Ancure). This was most evident by the availability
of non-contrast-enhanced images and by compliance with
the minimum resolution required by the core laboratory
and the respective trial. Although the presence of endoleak
was established by core laboratory analysis, both the ana-
lyzer and medical reviewer defined the specific type of
endoleak; however, results were not classified by endoleak
type in this study.
Baseline aneurysm size was determined from the first
post-implantation film, preferably before discharge. In the
absence of a pre-discharge study, 1-month or pre-implan-
tation studies were used. The temporal aspects of sac anat-
omy changes were analyzed with a nonlinear mixed mod-
el.12 This technique accounts for lack of independence of
measurements and allows for the potential for a nonlinear
pattern. The explanatory variables in the model included
type of endograft, presence or absence of endoleak, and
baseline sac size. The percentage of patients with endoleak
at any time during follow-up for specific prostheses were
compared with a 2 test.
RESULTS
Among 1506 patients evaluated, 723 patients (227
Ancure, 343 Excluder, 153 Zenith) met inclusion criteria
for this study. Average sac area was 2453 mm2 (Ancure,
2424 mm2; Excluder, 2475 mm2; Zenith, 2454 mm2).
Mean follow-up was 23.2 months; however, this varied
between devices (Ancure, 31.3 months; Excluder, 19.6
months; Zenith, 19.3 months). Overall incidence of en-
doleak at any time after device implantation was 39.1%
(Ancure, 58.1%; Excluder, 34.7%; Zenith 20.9%; P 
.001). The differences in endoleak incidence remained
significant after adjusting for differential follow-up time.
Type of prosthesis, presence or absence of endoleak,
and baseline aneurysm size all had independent affects on
the temporal behavior of the sac. Presence of endoleak
diminished the rate of size reduction with any type of
prosthesis. However, both of these observations were re-
lated to baseline aneurysm size. Fig 1 depicts the variation
in sac area change for the three prostheses in the presence
and absence of endoleak, assuming a baseline area of 2500
mm2 (corresponding to the area of a circular cross-section
with diameter 5.6 cm), which approximated the mean
aneurysm size for each trial. Fig 2 shows the behavior of the
sac for the three devices in the absence of endoleak, with
two arbitrary baseline sizes (2000 mm2 and 4000 mm2,
roughly consistent with aneurysms with circular cross-
Fig 1. Estimated sac behavior over time for the three devices, with and without presence of endoleak, for initial sac area
of 2500 mm2. Number of patients with measurements at different times per graft is noted.
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sectional areas with diameter 5.0 cm and 7.1 cm, respec-
tively). The model showed significant effects (P  .0001)
of all three variables (Table II). Average length (over time,
presence or absence of endoleak, device) of a 95% confi-
dence interval was 200 mm2 for aneurysms with baseline
size 2000 to 4000 mm2. Estimated change in size over time
for an aneurysm with baseline size 2500 mm2 appears in
Table III. A detail of the estimated model appears in Table
II (online only).
The following information can be derived from the
analysis:
● Of the three grafts, Excluder has the lowest rate of
decrease. Adjusting for baseline size, after 12 months sac
size decreases faster with the Zenith device than with the
Ancure device (P  .0001).
● The presence of an endoleak has a moderating effect on
rate of decrease of maximal cross-sectional area with the
Ancure and Zenith devices. For the Excluder, endoleak
tends to produce increase in sac size.
● Larger sacs tend to have greater area reduction, both in
absolute and relative terms. For example, an aneurysm
with 1000 mm2 more area than another aneurysm will
have, on average, a size reduction 6% greater at 24
months, regardless of graft type and presence or absence
of endoleak.
● Duration of follow-up was not long enough to deter-
mine an inflection point indicative of a plateau region.
DISCUSSION
Analysis of the various factors that affect aneurysm sac
behavior after endovascular aneurysm repair is complex. A
number of studies have presented single-center and multi-
center experiences comparing an assortment of prosthe-
ses.1,13 Prosthesis comparisons within these studies may be
limited, because of inconsistencies with respect to pre-
implantation anatomic differences, endovascular treatment
inclusion or exclusion criteria, and differing follow-up par-
adigms within clinical trials and, more specifically, when
commercial devices are used. Furthermore, multiple device
iterations were used during patient accrual in both of the
aforementioned series. The trial designs for all devices
evaluated in this study are similar with respect to anatomic
inclusion criteria. Although there are slight variations for
diameter limits at the intended fixation sites, the required
lengths and quality of the attachment sites were nearly
identical. Thus, by limiting our analysis to patients that met
the respective anatomic inclusion criteria for each trial, we
Fig 2. Estimated sac behavior over time for the three devices in absence of endoleak, for sac area of 2000 mm2 and
4000 mm2. Note differing rates of change associated with large and small aneurysms for each device. Results suggest
that decrease in size of large aneurysms will be greater than for small aneurysms.
Table III. Estimated changes in sac area for baseline sac
size of 2500 mm2
Expected size change (mm2)
6 Mo 12 Mo 24 Mo
Ancure without leak 168 322 597
Ancure with leak 119 232 439
Excluder without leak 36 72 142
Excluder with leak 18 37 75
Zenith without leak 279 523 924
Zenith with leak 132 440 796
Calculations are specific to baseline size of aneurysm. Approximate 95%
confidence intervals can be constructed as X 30, X 60, X 100 (where
X represents expected size change) for 6, 12, and 24 months of follow-up,
respectively.
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restricted any long-term analysis to patients with anatomi-
cally similar aneurysms. Additional relevance was accom-
plished by elimination of all predicate devices and aorto-
monoiliac systems from the analyses. These conditions were
established in an effort to produce a model that would
enable prediction of aneurysm sac behavior, when an endo-
prosthesis is implanted into a patient, if the clinicians ad-
here to the instructions for use of the respective device.
Clearly, each device had a unique effect on intermediate
and long-term aneurysm morphologic changes. All enjoyed
sac shrinkage in the absence of endoleak. The rate of
shrinkage was greatest with the Zenith device, followed by
the Ancure and Excluder devices, respectively (Fig 1).
There was a definitive effect of endoleak on aneurysm
anatomy that was also dependent on the prosthesis type and
baseline aneurysm size. In general, a moderating effect on
rate of size reduction was noted in the presence of a leak.
The slope for the Zenith and Ancure grafts remained
negative in the presence of an endoleak, implying that, on
average, the sacs should continue to shrink. An aneurysm
treated with an Excluder device would be expected to grow
slightly in the presence of a leak. Previous publications have
noted that the specific type of endoleak is a predictor of
clinical outcome and sac behavior.8,10,14-18 To make this
determination accurately, a detailed analysis of each en-
doleak is required, often necessitating coupling with addi-
tional imaging data, clinical information, and outcomes of
secondary interventions. This study was limited with re-
spect to details, and exclusively utilized CT follow-up. Thus
we were unable to establish definitive endoleak classifica-
tions. We therefore elected to not attempt to define en-
doleak types, and data for patients with endoleak at any
time were analyzed in a binary manner. This limits our
conclusions regarding the effect of endoleak to broad gen-
eralizations that include all types of leaks, and assumes that
there is a similar distribution of the types of endoleaks
among the three devices studied.
In the absence of persistent sac pressurization, it may be
predicted that the sac would shrink at a rate independent of
endograft construction. Several theories have been cited as
mechanisms for differential sac shrinkage rates.6,7,19-24
Type of graft material, presence or absence of structural
support, stent construct, modularity, main body length,
and inherent anatomy are all examples of potentially influ-
ential factors. Differential behaviors were noted for all three
grafts studied. The structural details of the prostheses stud-
ied have been reported.25-27 The two polyester grafts had
higher rates of decrease than did the expanded polytetra-
fluoroethylene (ePTFE) graft. However, the unsupported
polyester graft caused sac shrinkage to a lesser extent than
did the supported polyester graft. This contradicts any
assumption that presence or absence of support structures
is the main determinant of sac behavior. Similar arguments
can be made when considering modularity as a cause for
limiting aneurysm contraction, given the rate of sac shrink-
age of the two modular devices spanning the behavior of
the unibody device. In addition, all of the grafts used stents
with different composition, including nitinol (Excluder),
stainless steel (Zenith), and elgiloy (Ancure). Therefore we
can draw no conclusions regarding the effect of the metal
type on sac performance. It seems logical that the barrier
between systemic pressure and sac pressure would have
most influence on long-term behavior of the sac. Thus the
strongest factor affecting sac remodeling appears to relate
to use of differing fabrics, such as ePTFE or polyester.
Whether the limited sac shrinkage noted with the ePTFE
graft is related to characteristics specific to the particular
ePTFE construct, thickness of the material, more general
ePTFE properties, or a combination of design factors is
subject to speculation. Similar questions can be entertained
with respect to polyester grafts. The overall construct,
weave, yarn size, and warp vary, and therefore will have
different effects on depressurization of the aneurysm sac.
Perhaps these questions will be answered by future trials
incorporating variations of ePTFE and polyester con-
structs. Despite the detail and relative volume of patients
included in this analysis, we were not able to differentiate
the specific mechanisms that induced various effects on sac
behavior.
Despite the proposed benefits of volume measure-
ments,28 we used maximal area in conjunction with diam-
eter calculations to reflect size change. The primary reason
for this related to the overall intent of the core laboratory to
independently evaluate imaging data that correlates with
investigator measurement techniques. Area calculations
were obtained to further improve accuracy of diameter
measurements; however, many of the studies did not have
enough information to enable accurate volume measure-
ments. Of interest, area and maximum and minimum di-
ameter changes paralleled each other with respect to overall
behavior, but area was more temporally sensitive to change
than the other variables were.
Aneurysm shrinkage represents a reversal of the natural
history of the disease, and has long been considered the
herald of successful endovascular aneurysm repair. How-
ever, a strong note of caution must accompany this assump-
tion. Although it would be ludicrous to think that aneu-
rysm growth is beneficial, no direct correlation between
growth after endovascular grafting and rupture has been
determined.10 Dramatic changes in aneurysm size induce
morphologic changes that affect endograft position. This
has previously been implicated as a cause for failure (migra-
tion, kinking, limb thrombosis, component separation, du-
rability).29 Aneurysms remaining stable in size would, in
theory, have diminished risk for component separation and
new kinking.
Given the rather dramatic differences in rate of change
of aneurysm sac size, it is odd that follow-up protocols in
clinical use remain uniform. Most follow-up paradigms
have been simple extensions from the Phase II Food and
Drug Administration trials. However, it would seem pru-
dent to design paradigms that provide for intensive imaging
during periods of rapid morphologic change (in an effort to
detect fixation issues, potential for limb disunion, or limb
kinking and thrombosis), and become less rigorous during
periods of sac stability or in the setting of complete aneu-
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rysm regression. Few long-term data are available to sup-
port the current follow-up paradigms. It would seem pru-
dent to logically determine when patients are at highest risk
for potential adverse events related to aneurysm repair, and
during that time institute more intensive follow-up. In the
absence of material failure, the risk for serious morphologic
changes, device migration, or development of non-materi-
al-related leaks is anticipated to be decidedly low. However,
during regression, one is assured of lack of significant wall
pressurization, but there may be a false sense of security
regarding device stability. Once the potential for morpho-
logic changes is minimal, particularly in the setting of
complete aneurysm regression, material fatigue and aneu-
rysm size can be evaluated with differing follow-up para-
digms. Device integrity should continue to be assessed with
traditional radiographs, but the benefit of high-resolution
CT scans is limited to assessment of the diameter and graft
position with respect to the fixation sites. Ultrasound scans
may be used to define the status of the aneurysm, and
situations that are cause for concern, such as aneurysm
growth or new endoleak, should prompt further investiga-
tion. Thus, if aneurysm size change can be predicted, given
knowledge regarding initial size and endoleak status, even-
tually the duration of intensive follow-up required can be
determined. This has the potential to establish a finite end
point with respect to the indefinite accumulation of yearly
CT scans, limiting exposure to contrast agents and radia-
tion, and moderating the cost of follow-up. Ultimately, in
the absence of endoleak and a long enough patient life
span, this model predicts that all aneurysms will eventually
regress.
Several questions and study limitations must be recog-
nized. Inconsistent image quality associated with initial
study protocols, coupled with limited endovascular experi-
ence of implanting physicians, may have detrimentally af-
fected the Ancure trial, compared with the two more recent
studies. A steep learning curve with respect to the impor-
tance of high-resolution images, appropriately timed con-
trast medium boluses, and availability of non-contrast-
enhanced images was encountered. Imaging protocol
compliance improved over the course of all three studies as
greater emphasis was placed on the importance of fol-
low-up imaging by the centers, the core laboratory, and the
corporate sponsors. In addition to improved radiographic
compliance, our analysis methods evolved substantially.
Inconsistency with respect to both analysis and medical
review is inherent to aspects of each graft analysis. We
intentionally gave both the analyzers and the reviewers
latitude with respect to assessment of the subjective portion
of the analysis, and encouraged discussion among the re-
view team for a particular study so that unusual or complex
images were better assessed. As the analyzers became more
experienced, there were fewer conflicts between medical
reviewers and analyzers. A second layer of medical review,
an internal event adjudication procedure, was instituted,
and has provided a more thorough and accurate interpre-
tation of the radiographic data.
The statistical model used for temporal analysis was
selected to accommodate the lack of independence of ob-
servations within patient groups and to provide nonlinear
analysis of sac behavior. The ability to extrapolate device-
specific graphs beyond the duration of their follow-up may
help predict long-term sac behavior, but the accuracy of
such calculations is not certain. The data suggest a strong
downward trend even at later dates, and thus preclude
adequate estimation of a plateau.
These data are meant to provide guidelines for ex-
pected sac performance when treated with one of the three
studied prostheses. It is imperative to understand that
broad generalizations or expectations cannot be applied for
endovascular aneurysm repair with a variety of devices. The
differential device effect on the aneurysm sac must be
viewed in context of its predicted or expected performance
rather than a uniform assumption, unifying all endopros-
theses. It is critical that unusual behavior of an aneurysm sac
elicit concern and trigger an investigation into the cause.
Endoleak moderated sac shrinkage in all circumstances, but
with two of the three prostheses sac shrinkage continued in
the presence of such a leak. Thus, if the indication for a
secondary intervention is based on the presence of endoleak
presumably contributing to aneurysm growth, it must be
viewed in a prosthesis-specific manner. Furthermore, it may
be of benefit for follow-up protocols to remain intensive
during periods of rapid morphologic change, whereas dur-
ing phases of predictable sac behavior less rigorous imaging
methods may be used.
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